A Single-Arm, Multicenter, Open-Label, Phase II Clinical Study to Evaluate the Efficacy, Safety/Tolerability, and Pharmacokinetic Characteristics of GFH375 Monotherapy in Patients With Previously Treated KRAS G12D Mutant Metastatic Pancreatic Cancer
Latest Information Update: 25 Jun 2025
At a glance
- Drugs VS 7375 (Primary)
- Indications Pancreatic cancer
- Focus Therapeutic Use
- Sponsors GenFleet Therapeutics
Most Recent Events
- 25 Jun 2025 New trial record